Treatment completion rate (fraction of the cases with the continuation of the administration during the period and relative dose intensity ≥ 70%) (n = 97).
Continuation rate of S-1 administration at 100 days, 150 days and 200 days was 87.2%, 82.3% and 82.3% in Arm A and 84.2%, 79.1% and 70.9% in Arm B, respectively (